[go: up one dir, main page]

US20120114705A1 - Water soluble film for oral administration with instant wettability - Google Patents

Water soluble film for oral administration with instant wettability Download PDF

Info

Publication number
US20120114705A1
US20120114705A1 US13/292,590 US201113292590A US2012114705A1 US 20120114705 A1 US20120114705 A1 US 20120114705A1 US 201113292590 A US201113292590 A US 201113292590A US 2012114705 A1 US2012114705 A1 US 2012114705A1
Authority
US
United States
Prior art keywords
film according
film
water
group
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/292,590
Inventor
Horst Georg Zerbe
Jian-Hwa Guo
Anthony Serino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/292,590 priority Critical patent/US20120114705A1/en
Publication of US20120114705A1 publication Critical patent/US20120114705A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
    • A61K8/8176—Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90—Block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • a composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed.
  • the carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect.
  • the film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid dissolution/disintegration upon administration in the oral cavity.
  • Mucoadhesive dosage forms for application to the oral cavity which are designed to deliver therapeutic and/or cosmetic agents to the oral mucosa are known in the art.
  • U.S. Pat. No. 5,047,244 describes a mucoadhesive carrier allowing the controlled release of a therapeutic agent via the mucosal tissue comprising an anhydrous but hydratable polymer matrix and amorphous fumed silica.
  • An optional water-insoluble film can be added to provide a non-adhering surface.
  • WO 91/06270 the same authors disclose a trilaminate film suitable for prolonged delivery of an active ingredient in the oral cavity.
  • U.S. Pat. No. 4,876,092 discloses a sheet-shaped adhesive preparation comprising an adhesive layer containing certain water-soluble and water-insoluble polymers and a water-insoluble carrier which can adhere to the oral mucosa thereby releasing an active agent to the oral cavity. All the devices so far cited are not completely water soluble and will stay in the oral cavity even after the therapeutic goal has been achieved leaving the patient with a certain discomfort in the mouth resulting mainly from the support layer which leaves an insoluble residue in the mouth.
  • EP 0 200 508 B1 and EP 0 381 194 B1 disclose the use of polyethylene films, polyvinyl acetate, ethylene-vinyl acetate copolymers, metal foils, laminates of cloth or paper and a plastic film, and similar materials as soft film supports, whereby synthetic resins like polyethylene, vinyl acetate homopolymers, and ethylene-vinyl acetate are the preferred materials.
  • CA 1 263 312 discloses the use of polyolefines such as polyethylene, polypropylene, polyesters, PVC, and non-woven fabrics as soft support materials.
  • Both DE 36 30 603 and EP 0 219 762 disclose the use of swellable polymers such as gelatine or corn starch as film forming agents, which upon application to the oral cavity slowly disintegrate, thereby releasing an active ingredient incorporated in the film.
  • swellable polymers such as gelatine or corn starch
  • the same polymers can also be used to prepare films which are intended for dental cleansing, as described in EP 0 452 446 B1.
  • the present invention discloses methods and compositions that are capable of avoiding an adverse feeling by providing the film which is intended for application to the oral mucosa with instant wettability, while achieving adequate tensile strength in the free film to allow for easy coating, converting, and packaging of a consumer-friendly product.
  • the present invention contemplates a rapidly dissolving film which can be adhered to the oral cavity thereby releasing a pharmaceutically or cosmetically active agent, said film comprising water-soluble polymers, one or more polyalcohols, and one or more pharmaceutically or cosmetically active ingredients.
  • the formulation may contain a combination of certain plasticizers or surfactants, colorants, sweetening agents, flavors, flavor enhancers, or other excipients commonly used to modify the taste of formulations intended for application to the oral cavity.
  • the resulting film is characterized by an instant wettability which causes the film to soften immediately after application to the mucosal tissue thus preventing the patient from experiencing any prolonged adverse feeling in the mouth, and a tensile strength suitable for normal coating, cutting, slitting, and packaging operations.
  • the mucoadhesive film of the present invention contains as essential components a water-soluble polymer or a combination of water-soluble polymers, one or more plasticizers or surfactants, one or more polyalcohols, and a pharmaceutically or cosmetically active ingredient.
  • the polymers used for the mucoadhesive film include polymers which are hydrophilic and/or water-dispersible.
  • Preferred polymers are water-soluble cellulose-derivatives. Hydroxypropylmethyl cellulose, hydroxyethyl cellulose, or hydroxypropyl cellulose, either alone, or mixtures thereof, are particularly preferred.
  • polymers include polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, natural gums like xanthane gum, tragacantha, guar gum, acacia gum, arabic gum, water-dispersible polyacrylates like polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers.
  • concentration of the water-soluble polymer in the final film can vary between 20 and 75% (w/w), preferably between 50 and 75% (w/w).
  • the surfactants used for the mucoadhesive film may be one or more nonionic surfactants.
  • the first component may be a polyoxyethylene sorbitan fatty acid ester or a ⁇ -hydro- ⁇ -hydroxypoly(oxyethylene) poly(oxypropylene)poly(oxyethylene) block copolymer
  • the second component may be a polyoxyethylene alkyl ether or a polyoxyethylene castor oil derivative.
  • the HLB value of the polyoxyethylene sorbitan fatty acid ester should be between 10 and 20, whereby a range of 13 to 17 is particularly preferred.
  • the ⁇ -hydro- ⁇ -hydroxypoly(oxyethylene)poly(oxypropylene) poly(oxyethylene) block copolymer should contain at least 35 oxypropylene-units, preferably not less than 50 oxypropylene-units.
  • the polyoxyethylene alkyl ether should have an HLB value between 10 and 20, whereby an HLB value of not less than 15 is preferred.
  • the polyoxyethylene castor oil derivative has to have an HLB value of 14-16.
  • the ratio between the first and second component of the binary surfactant mixture should be kept within 1:10 and 1:1, more preferably between 1:5 and 1:3.
  • the total concentration of surfactants in the final film depends on the properties of the other ingredients, but usually has to stay between 0.1 and 5% (w/w).
  • the polyalcohol is used to achieve the desired level of softness of the film.
  • examples of polyalcohols include glycerol, polyethylene glycol, propylene glycol, glycerol monoesters with fatty acids or other pharmaceutically used polyalcohols.
  • concentration of the polyalcohol in the dry film usually ranges between 0.1 and 5% (w/w).
  • the film is well suited for the delivery of a wide range of pharmaceutically active ingredients via the mucous membranes of a patient, particularly the buccal mucosa.
  • Therapeutic agents which exhibit absorption problems due to solubility limitations, degradation in the gastro-intestinal tract, or extensive metabolism, are particularly well suited.
  • examples of the therapeutic agents include hypnotics, sedatives, antiepileptics, awakening agents, psychoneurotropic agents, neuromuscular blocking agents, antispasmodic agents, antihistaminics, antiallergics, cardiotonics, antiarrhythmics, diuretics, hypotensives, vasopressors, antitussive expectorants, thyroid hormones, sexual hormones, antidiabetics, antitumor agents, antibiotics and chemotherapeutics, and narcotics.
  • the amount of drug to be incorporated into the film depends on the kind of drug and is usually between 0.01 and 20% (w/w), but it can be higher if necessary to achieve the desired effect.
  • Cosmetically active agents may include breath freshening compounds like menthol, other flavors or fragrances commonly used for oral hygiene, and/or actives used for dental and/or oral cleansing like quarternary ammonium bases.
  • flavors may be enhanced using flavor enhancers like tartaric acid, citric acid, vanillin, or the like.
  • Colorants which may optionally be mixed in the film must be safe in terms of toxicity and should be accepted by the Food and Drug Administration for use in cosmetics.
  • the mucoadhesive film according to the present invention can be prepared as follows: The polyalcohol, surfactants, plasticizers, and possible other ingredients except the water-soluble or water-dispersible polymer(s) are dissolved in a sufficient amount of a solvent which is compatible with them. Examples of compatible solvents include water, alcohols or mixtures thereof. After a clear solution has been formed, the water-dispersible polymer or mixture of the water-dispersible polymers is slowly added with stirring, and heat if necessary, until a clear and homogeneous solution has been formed, followed by the addition of active ingredients and flavors. The solution is coated onto a suitable carrier material and dried to form a film.
  • the carrier material must have a surface tension which allows the polymer solution to spread evenly across the intended coating width without soaking in to form a destructive bond between the two.
  • suitable materials include non-siliconized polyethylene terephthalate film, non-siliconized kraft paper, polyethylene-impregnated kraft paper, or non-siliconized polyethylene film.
  • the coating of the solution onto the carrier material can be performed using any conventional coating equipment.
  • a more preferred coating technique would involve a knife-over-roll coating head.
  • the thickness of the resulting film depends on the concentration of solids in the coating solution and on the gap of the coating head and can vary between 5 and 200 ⁇ m. Drying of the film is carried out in a high-temperature air-bath using a drying oven, drying tunnel, vacuum drier, or any other suitable drying equipment, which does not adversely affect the active ingredient(s) or flavor of the film. In order to reliably avoid an adverse feeling in the mouth, a dry film thickness of 70 ⁇ m should not be exceeded.
  • the dry film can be cut into pieces of suitable size and shape and packed into a suitable container.
  • Coating gap and web speed have to be adjustable to achieve a dry film thickness between 20 and 50 ⁇ m.
  • the drying temperature depends on the length of the drying oven and the web speed and has to be adjusted to remove the solvents completely, or almost completely, from the film.
  • the resulting film is peeled off the carrier web and cut into pieces of a shape and size suitable for the intended use.
  • 3 g sorbitol, 1.5 g Kollidon 30 (supplier: BASF), 5 g glycerol, 5 g propylene glycol, 5 g polyethylene glycol, 4 g polysorbate 80 (Tween 80), 8 g Brij 35, 12 g peppermint flavor, and 0.8 g aspartame are dissolved in a mixture containing 400 g water and 400 g ethanol at 60° C. under stirring.
  • 28 g hydroxypropylmethyl cellulose are added slowly under stirring.
  • the solution is cooled to room temperature and coated onto a suitable carrier web using the coating and drying conditions as described in the previous example. The dry film is again cut into pieces of suitable size and shape.
  • 165.4 g Kollidon 30 are dissolved in a solution of 720 ml water and 2660 ml ethanol at ambient temperature with stirring. 220.5 g hydroxypropylmethyl cellulose is then added at 55-60° C. and stirred vigorously until clear and homogeneous. The mixture is then allowed to cool and added in succession are 78.75 g flavor followed by a mixture of 28.88 g nicotine salicylate and 31.5 g caramel liquid in 120 ml water with stirring. The clear, tan-colored solution is coated an dried under the conditions as described in EXAMPLE 1 and the dry film is cut into pieces of a shape and size suitable for the intended use so as to deliver a nicotine dose between 1-2 mg per piece.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Dental Preparations (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed. The carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect. The film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid dissolution/disintegration upon administration in the oral cavity.

Description

  • A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed. The carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect. The film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid dissolution/disintegration upon administration in the oral cavity.
  • Mucoadhesive dosage forms for application to the oral cavity which are designed to deliver therapeutic and/or cosmetic agents to the oral mucosa are known in the art. U.S. Pat. No. 5,047,244 describes a mucoadhesive carrier allowing the controlled release of a therapeutic agent via the mucosal tissue comprising an anhydrous but hydratable polymer matrix and amorphous fumed silica. An optional water-insoluble film can be added to provide a non-adhering surface. In WO 91/06270, the same authors disclose a trilaminate film suitable for prolonged delivery of an active ingredient in the oral cavity.
  • In a similar way, U.S. Pat. No. 4,876,092 discloses a sheet-shaped adhesive preparation comprising an adhesive layer containing certain water-soluble and water-insoluble polymers and a water-insoluble carrier which can adhere to the oral mucosa thereby releasing an active agent to the oral cavity. All the devices so far cited are not completely water soluble and will stay in the oral cavity even after the therapeutic goal has been achieved leaving the patient with a certain discomfort in the mouth resulting mainly from the support layer which leaves an insoluble residue in the mouth.
  • A number of attempts have been made to reduce the adverse feeling in the oral cavity caused by the rigidity and inflexibility of the support layer by introducing soft film supports. EP 0 200 508 B1 and EP 0 381 194 B1 disclose the use of polyethylene films, polyvinyl acetate, ethylene-vinyl acetate copolymers, metal foils, laminates of cloth or paper and a plastic film, and similar materials as soft film supports, whereby synthetic resins like polyethylene, vinyl acetate homopolymers, and ethylene-vinyl acetate are the preferred materials. In a similar way, CA 1 263 312 discloses the use of polyolefines such as polyethylene, polypropylene, polyesters, PVC, and non-woven fabrics as soft support materials.
  • However, these devices still leave the patient with a considerable amount of residue from the water-insoluble support film thereby still causing a feeling of discomfort. The obvious solution to overcome this problem was to develop mucoadhesive films which completely disintegrate, or even completely dissolve in the saliva. Fuchs and Hilmann (DE 24 49 865.5) prepared homogeneous, water-soluble films intended for buccal administration of hormones. They proposed the use of water-soluble cellulose-derivatives, like hydroxyethyl cellulose, hydroxypropyl cellulose, or methyl hydroxypropyl cellulose, as film forming agents.
  • Both DE 36 30 603 and EP 0 219 762 disclose the use of swellable polymers such as gelatine or corn starch as film forming agents, which upon application to the oral cavity slowly disintegrate, thereby releasing an active ingredient incorporated in the film. The same polymers can also be used to prepare films which are intended for dental cleansing, as described in EP 0 452 446 B1.
  • These preparations still create an adverse feeling in the mouth which is mainly caused by their initial rigidity and delayed softening. Thus, there has still been a demand for a composition for use in the oral cavity which meets the requirement of providing a pleasant feeling in the mouth.
  • The present invention discloses methods and compositions that are capable of avoiding an adverse feeling by providing the film which is intended for application to the oral mucosa with instant wettability, while achieving adequate tensile strength in the free film to allow for easy coating, converting, and packaging of a consumer-friendly product.
  • The present invention contemplates a rapidly dissolving film which can be adhered to the oral cavity thereby releasing a pharmaceutically or cosmetically active agent, said film comprising water-soluble polymers, one or more polyalcohols, and one or more pharmaceutically or cosmetically active ingredients. Optionally, the formulation may contain a combination of certain plasticizers or surfactants, colorants, sweetening agents, flavors, flavor enhancers, or other excipients commonly used to modify the taste of formulations intended for application to the oral cavity. The resulting film is characterized by an instant wettability which causes the film to soften immediately after application to the mucosal tissue thus preventing the patient from experiencing any prolonged adverse feeling in the mouth, and a tensile strength suitable for normal coating, cutting, slitting, and packaging operations.
  • The mucoadhesive film of the present invention contains as essential components a water-soluble polymer or a combination of water-soluble polymers, one or more plasticizers or surfactants, one or more polyalcohols, and a pharmaceutically or cosmetically active ingredient.
  • The polymers used for the mucoadhesive film include polymers which are hydrophilic and/or water-dispersible. Preferred polymers are water-soluble cellulose-derivatives. Hydroxypropylmethyl cellulose, hydroxyethyl cellulose, or hydroxypropyl cellulose, either alone, or mixtures thereof, are particularly preferred. Other optional polymers, without limiting the invention, include polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, natural gums like xanthane gum, tragacantha, guar gum, acacia gum, arabic gum, water-dispersible polyacrylates like polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers. The concentration of the water-soluble polymer in the final film can vary between 20 and 75% (w/w), preferably between 50 and 75% (w/w).
  • The surfactants used for the mucoadhesive film may be one or more nonionic surfactants. When a combination of surfactants is used, the first component may be a polyoxyethylene sorbitan fatty acid ester or a α-hydro-ω-hydroxypoly(oxyethylene) poly(oxypropylene)poly(oxyethylene) block copolymer, while the second component may be a polyoxyethylene alkyl ether or a polyoxyethylene castor oil derivative. Preferably, the HLB value of the polyoxyethylene sorbitan fatty acid ester should be between 10 and 20, whereby a range of 13 to 17 is particularly preferred. The α-hydro-ω-hydroxypoly(oxyethylene)poly(oxypropylene) poly(oxyethylene) block copolymer should contain at least 35 oxypropylene-units, preferably not less than 50 oxypropylene-units.
  • The polyoxyethylene alkyl ether should have an HLB value between 10 and 20, whereby an HLB value of not less than 15 is preferred. The polyoxyethylene castor oil derivative has to have an HLB value of 14-16.
  • In order to achieve the desired instant wettability, the ratio between the first and second component of the binary surfactant mixture should be kept within 1:10 and 1:1, more preferably between 1:5 and 1:3.
  • The total concentration of surfactants in the final film depends on the properties of the other ingredients, but usually has to stay between 0.1 and 5% (w/w).
  • The polyalcohol is used to achieve the desired level of softness of the film. Examples of polyalcohols include glycerol, polyethylene glycol, propylene glycol, glycerol monoesters with fatty acids or other pharmaceutically used polyalcohols. The concentration of the polyalcohol in the dry film usually ranges between 0.1 and 5% (w/w).
  • The film is well suited for the delivery of a wide range of pharmaceutically active ingredients via the mucous membranes of a patient, particularly the buccal mucosa. Therapeutic agents which exhibit absorption problems due to solubility limitations, degradation in the gastro-intestinal tract, or extensive metabolism, are particularly well suited. Without limiting the invention, examples of the therapeutic agents include hypnotics, sedatives, antiepileptics, awakening agents, psychoneurotropic agents, neuromuscular blocking agents, antispasmodic agents, antihistaminics, antiallergics, cardiotonics, antiarrhythmics, diuretics, hypotensives, vasopressors, antitussive expectorants, thyroid hormones, sexual hormones, antidiabetics, antitumor agents, antibiotics and chemotherapeutics, and narcotics.
  • The amount of drug to be incorporated into the film depends on the kind of drug and is usually between 0.01 and 20% (w/w), but it can be higher if necessary to achieve the desired effect.
  • Cosmetically active agents may include breath freshening compounds like menthol, other flavors or fragrances commonly used for oral hygiene, and/or actives used for dental and/or oral cleansing like quarternary ammonium bases. The effect of flavors may be enhanced using flavor enhancers like tartaric acid, citric acid, vanillin, or the like. Colorants which may optionally be mixed in the film must be safe in terms of toxicity and should be accepted by the Food and Drug Administration for use in cosmetics.
  • The mucoadhesive film according to the present invention can be prepared as follows: The polyalcohol, surfactants, plasticizers, and possible other ingredients except the water-soluble or water-dispersible polymer(s) are dissolved in a sufficient amount of a solvent which is compatible with them. Examples of compatible solvents include water, alcohols or mixtures thereof. After a clear solution has been formed, the water-dispersible polymer or mixture of the water-dispersible polymers is slowly added with stirring, and heat if necessary, until a clear and homogeneous solution has been formed, followed by the addition of active ingredients and flavors. The solution is coated onto a suitable carrier material and dried to form a film. The carrier material must have a surface tension which allows the polymer solution to spread evenly across the intended coating width without soaking in to form a destructive bond between the two. Examples of suitable materials include non-siliconized polyethylene terephthalate film, non-siliconized kraft paper, polyethylene-impregnated kraft paper, or non-siliconized polyethylene film.
  • The coating of the solution onto the carrier material can be performed using any conventional coating equipment. A more preferred coating technique would involve a knife-over-roll coating head.
  • The thickness of the resulting film depends on the concentration of solids in the coating solution and on the gap of the coating head and can vary between 5 and 200 μm. Drying of the film is carried out in a high-temperature air-bath using a drying oven, drying tunnel, vacuum drier, or any other suitable drying equipment, which does not adversely affect the active ingredient(s) or flavor of the film. In order to reliably avoid an adverse feeling in the mouth, a dry film thickness of 70 μm should not be exceeded.
  • For better ease of use, the dry film can be cut into pieces of suitable size and shape and packed into a suitable container.
  • The invention will now be explained more specifically with reference to the following examples, which are given for illustration of this invention and are not intended to be limiting thereof.
    • EXAMPLE 1
  • 15 g of sorbitol, 6 g of glycerol, 0.5 g of polysorbate 80 (Tween 80), 2 g of Brij 35, 25 g of lemon mint flavor, 3 g of aspartame, 15 g of 1-menthol, and 3 g of citrc acid are stirred at 60° C. in a mixture of 250 g water and 250 g ethanol until a clear solution has been formed. To the solution, 30 g of hydroxypropylmethyl cellulose are added slowly under stirring until a clear and homogeneous solution has been formed. The resulting solution is allowed to cool to room temperature and coated onto a suitable carrier material, for example non-siliconized, polyethylene-coated kraft paper using conventional coating/drying equipment. Coating gap and web speed have to be adjustable to achieve a dry film thickness between 20 and 50 μm. The drying temperature depends on the length of the drying oven and the web speed and has to be adjusted to remove the solvents completely, or almost completely, from the film. The resulting film is peeled off the carrier web and cut into pieces of a shape and size suitable for the intended use.
    • EXAMPLE 2
  • 3 g sorbitol, 1.5 g Kollidon 30 (supplier: BASF), 5 g glycerol, 5 g propylene glycol, 5 g polyethylene glycol, 4 g polysorbate 80 (Tween 80), 8 g Brij 35, 12 g peppermint flavor, and 0.8 g aspartame are dissolved in a mixture containing 400 g water and 400 g ethanol at 60° C. under stirring. To the clear solution, 28 g hydroxypropylmethyl cellulose are added slowly under stirring. After the polymer is completely dissolved, the solution is cooled to room temperature and coated onto a suitable carrier web using the coating and drying conditions as described in the previous example. The dry film is again cut into pieces of suitable size and shape.
    • EXAMPLE 3
  • 15 g sorbitol, 22.5 g glycerol, 2.5 g propylene glycol, 2.5 g Brij 35, 2.5 g polyoxamer 407, 3.5 g Cremophor RH 40, 9 g herb mint flavor, and 0.5 g aspartame are dissolved under stirring at 60° C. in a mixture containing 250 g water and 250 g ethanol. To the clear solution, 75 g hydroxypropyl cellulose are added slowly under continuous stirring. The clear solution is again coated and dried under the conditions as described in EXAMPLE 1 and the dry film is cut into pieces of a shape and size suitable for the intended use.
    • EXAMPLE 4
  • 3.6 g Tween 80, 3.6 g glycerol, 39 g menthol, and 171 g Kollidon 30 are dissolved in a solution of 600 ml water and 2800 ml ethanol at ambient temperature with stirring. 247.5 g hydroxypropylmethyl cellulose is then added slowly and portionwise at 50-55° C. and stirred until completely dissolved. The mixture is then allowed to cool and added in succession are 90 g lemon mint flavor followed by a solution/suspension of 27.13 g aspartame, 18 g citric acid, and 0.17 g FD&C yellow #5 in 120 ml water with stirring. The clear solution is coated and dried under the conditions as described in EXAMPLE and the dry film is cut into pieces of a shape and size suitable for the intended use.
    • EXAMPLE 5
  • 165.4 g Kollidon 30 are dissolved in a solution of 720 ml water and 2660 ml ethanol at ambient temperature with stirring. 220.5 g hydroxypropylmethyl cellulose is then added at 55-60° C. and stirred vigorously until clear and homogeneous. The mixture is then allowed to cool and added in succession are 78.75 g flavor followed by a mixture of 28.88 g nicotine salicylate and 31.5 g caramel liquid in 120 ml water with stirring. The clear, tan-colored solution is coated an dried under the conditions as described in EXAMPLE 1 and the dry film is cut into pieces of a shape and size suitable for the intended use so as to deliver a nicotine dose between 1-2 mg per piece.

Claims (38)

1-9. (canceled)
10. A film comprising:
i. at least one water-soluble polymer,
ii. at least one polyalcohol, and
iii. at least one pharmaceutically active ingredient.
11. A film according to claim 10 wherein the at least one polyalcohol is selected from the group consisting of glycerol, propylene glycol, glycerol esters with fatty acids and other pharmaceutically used polyalcohols.
12. A film according to claim 11 wherein the concentration of the at least one water-soluble polymer is between 20 and 75% (w/w).
13. A film according to claim 11 wherein the concentration of the at least one polyalcohol is between 0.1 and 5% (w/w).
14. A film according to claim 10 wherein the concentration of at least one pharmaceutically active ingredient is between 0.01 and 20% (w/w).
15. A film according to claim 10 wherein at least one pharmaceutically active ingredient is selected from the group of narcotics.
16. A film according to claim 10 wherein the film has a thickness between 5 and 200 μm.
17. A film according to claim 16 wherein the film has a thickness between 5 and 70 μm.
18. A film according to claim 10 further comprising at least one member of the group consisting of colorants, sweetening agents, flavours, and flavour enhancers.
19. A film according to claim 10 further comprising tartaric acid.
20. A film according to claim 10 further comprising citric acid.
21. A film according to claim 10 further comprising vanillin.
22. A film according to claim 10 wherein
i. a first water-soluble polymer is a water-soluble cellulose derivative and
ii. a second water-soluble polymer is selected from the group consisting of polyvinyl pyrrolidone, polyvinyl alcohol and polyethylene glycol.
23. A film according to claim 22 wherein the water-soluble cellulose derivative is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose.
24. A film according to claim 10 wherein a first water-soluble polymer is hydroxypropylmethyl cellulose and a second water-soluble polymer is polyethylene glycol.
25. A film according to claim 10 wherein the film is capable to release at least one pharmaceutically active ingredient to the oral cavity.
26. A film according to claim 10 wherein the film is rapidly dissolving.
27. A film according to claim 10 wherein the film is mucoadhesive.
28. A film comprising
i. a first water-soluble polymer which is a water-soluble cellulose derivative selected from the group consisting of hydroxypropylmethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose,
ii. a second water-soluble polymer which is selected from the group consisting of polyvinyl pyrrolidone, polyvinyl alcohol and polyethylene glycol, and
iii. at least one pharmaceutically active ingredient.
29. A film according to claim 28 wherein at least one pharmaceutically active ingredient is selected from the group of narcotics.
30. A film according to claim 28 wherein a first water-soluble polymer is hydroxypropylmethyl cellulose and a second water-soluble polymer is polyethylene glycol.
31. A film according to claim 28 wherein the concentration of at least one water-soluble polymer is between 20 and 75% (w/w).
32. A film according to claim 28 wherein the concentration of polyethylene glycol is between 20 and 75% (w/w).
33. A film according to claim 28 further comprising at least one polyalcohol.
34. A film according to claim 28 wherein the concentration of the at least one pharmaceutically active ingredient is between 0.01 and 20% (w/w).
35. A film according to claim 28 wherein the concentration of at least one pharmaceutically active ingredient selected from the group of narcotics is between 0.01 and 20% (w/w).
36. A film according to claim 28 wherein the film has a thickness between 5 and 200 μm.
37. A film according to claim 36 wherein the film has a thickness of between 5 and 70 μm.
38. A film according to claim 28 further comprising at least one member of the group consisting of colorants, sweetening agents, flavours, and flavour enhancers.
39. A film according to claim 28 further comprising tartaric acid.
40. A film according to claim 28 further comprising citric acid.
41. A film according to claim 28 further comprising vanillin.
42. A film according to claim 28 wherein the film is capable to release the at least one pharmaceutically active ingredient to the oral cavity.
43. A film according to claim 28 wherein the film is rapidly dissolving.
44. A film according to claim 28 wherein the film is mucoadhesive.
45. A film comprising:
i. at least one water-soluble hydroxypropylmethyl cellulose,
ii. at least one water-soluble polyethylene glycol in a concentration of between 20 and 75% (w/w),
iii. and at least one pharmaceutically active ingredient selected from the group of narcotics in a concentration of between 0.01 and 20% (w/w).
46. A film according to claim 45 further comprising at least one polyalcohol, at least one colorant, at least one sweetening agent, and citric acid.
US13/292,590 1996-11-11 2011-11-09 Water soluble film for oral administration with instant wettability Abandoned US20120114705A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/292,590 US20120114705A1 (en) 1996-11-11 2011-11-09 Water soluble film for oral administration with instant wettability

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DE19646392A DE19646392A1 (en) 1996-11-11 1996-11-11 Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery
DE19646392.0 1996-11-11
US08/904,607 US5948430A (en) 1996-11-11 1997-08-01 Water soluble film for oral administration with instant wettability
US09/287,181 US6177096B1 (en) 1996-11-11 1999-04-06 Water soluble film for oral administration with instant wettability
US09/630,562 US6284264B1 (en) 1996-11-11 2000-08-02 Water soluble film for oral administration with instant wettability
US09/927,327 US20010046511A1 (en) 1996-11-11 2001-08-13 Water soluble film for oral administration with instant wettability
US10/143,962 US6709671B2 (en) 1996-11-11 2002-05-14 Water soluble film for oral administration with instant wettability
US10/771,388 US8865202B2 (en) 1996-11-11 2004-02-05 Water soluble film for oral administration with instant wettability
US13/292,590 US20120114705A1 (en) 1996-11-11 2011-11-09 Water soluble film for oral administration with instant wettability

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/771,388 Division US8865202B2 (en) 1996-11-11 2004-02-05 Water soluble film for oral administration with instant wettability

Publications (1)

Publication Number Publication Date
US20120114705A1 true US20120114705A1 (en) 2012-05-10

Family

ID=7811214

Family Applications (8)

Application Number Title Priority Date Filing Date
US08/904,607 Expired - Lifetime US5948430A (en) 1996-11-11 1997-08-01 Water soluble film for oral administration with instant wettability
US09/287,181 Expired - Lifetime US6177096B1 (en) 1996-11-11 1999-04-06 Water soluble film for oral administration with instant wettability
US09/630,562 Expired - Lifetime US6284264B1 (en) 1996-11-11 2000-08-02 Water soluble film for oral administration with instant wettability
US09/927,327 Abandoned US20010046511A1 (en) 1996-11-11 2001-08-13 Water soluble film for oral administration with instant wettability
US10/143,962 Expired - Lifetime US6709671B2 (en) 1996-11-11 2002-05-14 Water soluble film for oral administration with instant wettability
US10/161,670 Expired - Lifetime US6592887B2 (en) 1996-11-11 2002-06-05 Water soluble film for oral administration with instant wettability
US10/771,388 Expired - Fee Related US8865202B2 (en) 1996-11-11 2004-02-05 Water soluble film for oral administration with instant wettability
US13/292,590 Abandoned US20120114705A1 (en) 1996-11-11 2011-11-09 Water soluble film for oral administration with instant wettability

Family Applications Before (7)

Application Number Title Priority Date Filing Date
US08/904,607 Expired - Lifetime US5948430A (en) 1996-11-11 1997-08-01 Water soluble film for oral administration with instant wettability
US09/287,181 Expired - Lifetime US6177096B1 (en) 1996-11-11 1999-04-06 Water soluble film for oral administration with instant wettability
US09/630,562 Expired - Lifetime US6284264B1 (en) 1996-11-11 2000-08-02 Water soluble film for oral administration with instant wettability
US09/927,327 Abandoned US20010046511A1 (en) 1996-11-11 2001-08-13 Water soluble film for oral administration with instant wettability
US10/143,962 Expired - Lifetime US6709671B2 (en) 1996-11-11 2002-05-14 Water soluble film for oral administration with instant wettability
US10/161,670 Expired - Lifetime US6592887B2 (en) 1996-11-11 2002-06-05 Water soluble film for oral administration with instant wettability
US10/771,388 Expired - Fee Related US8865202B2 (en) 1996-11-11 2004-02-05 Water soluble film for oral administration with instant wettability

Country Status (25)

Country Link
US (8) US5948430A (en)
EP (2) EP1362584B1 (en)
JP (3) JP4063331B2 (en)
KR (2) KR100604995B1 (en)
AT (2) ATE422157T1 (en)
AU (1) AU739698B2 (en)
CA (1) CA2265651C (en)
CZ (1) CZ297354B6 (en)
DE (4) DE19646392A1 (en)
DK (2) DK1362584T3 (en)
ES (2) ES2322699T3 (en)
HU (2) HU228464B1 (en)
ID (1) ID22526A (en)
IL (2) IL129819A0 (en)
MY (1) MY125548A (en)
NO (2) NO325073B1 (en)
NZ (1) NZ335063A (en)
PL (1) PL190376B1 (en)
PT (2) PT1362584E (en)
SI (1) SI0936905T1 (en)
SK (2) SK285999B6 (en)
TR (1) TR199901633T2 (en)
TW (2) TW533083B (en)
WO (1) WO1998020862A1 (en)
ZA (1) ZA9710093B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121660A1 (en) * 2017-12-20 2019-06-27 Firmenich Sa Oral care compositions
US11129799B2 (en) 2011-04-12 2021-09-28 Aquestive Therapeutics, Inc. Dual lane coating
US11723863B2 (en) 2018-06-22 2023-08-15 Church & Dwight Co., Inc. Oral care compositions comprising benzocaine and mucoadhesive thin films formed therefrom

Families Citing this family (414)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636001A1 (en) * 1996-09-05 1998-03-12 Hoechst Ag Polymer mixtures containing sulfoxide groups
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19646392A1 (en) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
DE19832169A1 (en) * 1998-07-17 2000-01-27 Jenapharm Gmbh Treating or preventing oral atrophic symptoms, e.g. marginal periodontal disease, by local administration of estrogen such as estriol
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US20020098264A1 (en) * 1998-11-27 2002-07-25 Cherukuri Subraman R. Medicated chewing gum delivery system for nicotine
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
US20030206942A1 (en) * 1998-09-25 2003-11-06 Neema Kulkarni Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
MXPA01005346A (en) * 1998-11-27 2003-03-27 Kanji Takada An oral formulation for gastrointestinal drug delivery.
DE19856101A1 (en) * 1998-12-04 2000-06-08 Labtec Gmbh Patch for local administration of drugs in the oral cavity includes a drug-containing matrix comprising a water-insoluble cellulose ether and a water-soluble cellulose ether in a defined ratio
ES2337322T3 (en) 1998-12-23 2010-04-22 Mount Sinai School Of Medicine Of New York University INHIBITORS OF THE AMARGO FLAVOR RESPONSE.
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
EP1152749B1 (en) † 1999-02-08 2006-04-12 ALZA Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
DE19911262C2 (en) * 1999-03-13 2003-04-10 Scs Skin Care Systems Gmbh Device for dispensing cosmetic active ingredients
US6231957B1 (en) 1999-05-06 2001-05-15 Horst G. Zerbe Rapidly disintegrating flavor wafer for flavor enrichment
BR0012145A (en) 1999-07-02 2002-04-30 Procter & Gamble Oral treatment composition delivery system comprising organosiloxane resins using a removable backing tape
US7314716B2 (en) 1999-11-19 2008-01-01 Mount Sinai School Of Medicine Gustducin γ subunit materials and methods
DE10001096A1 (en) * 2000-01-13 2001-07-26 Lohmann Therapie Syst Lts Transdermal therapeutic system for prolonged release of drugs, e.g. steroid hormones, including reservoir providing slow release of perfume to improve patient compliance
US6387356B1 (en) 2000-01-27 2002-05-14 Colgate-Palmolive Company Cosmetic composition
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
DE10032456A1 (en) * 2000-07-04 2002-01-31 Lohmann Therapie Syst Lts Rapidly disintegrating dosage form for the release of active substances in the mouth or in the body cavities
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
DE10034491A1 (en) * 2000-07-15 2002-01-24 Scs Skin Care Systems Gmbh Foil dermatics
DE10050267A1 (en) * 2000-10-09 2001-12-06 Karen Croissant Dental and/or oral cleaning agent, such as toothpaste, tooth gel, tooth powder, medicinal chewing gum, mouthwash, mouth powder, mouth pill or toothpick, comprises psychopharmaceutical
US20020131990A1 (en) * 2000-11-30 2002-09-19 Barkalow David G. Pullulan free edible film compositions and methods of making the same
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20060062864A1 (en) * 2000-12-28 2006-03-23 Mccleary Edward L Weight loss composition and method
WO2002054997A1 (en) * 2001-01-09 2002-07-18 Lavipharm Laboratories Inc. Devices for local and systemic delivery of active substances and methods of manufacturing thereof
DE10107659B4 (en) 2001-02-19 2008-03-13 Lts Lohmann Therapie-Systeme Ag Mucoadhesive disintegratable drug preparation for drug administration in veterinary and human medicine
US20060110478A1 (en) * 2004-11-22 2006-05-25 Mccleary Edward L Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction
US20030068376A1 (en) * 2001-04-20 2003-04-10 Lavipharm Laboratories Inc. Intraoral delivery of nicotine for smoking cessation
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
DE60239528D1 (en) 2001-05-01 2011-05-05 Corium International Redwood City TWO-PHASE, WATER-ABSORBING BIOADHESIVE COMPOSITION
CA2445086C (en) 2001-05-01 2008-04-08 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US6660292B2 (en) * 2001-06-19 2003-12-09 Hf Flavoring Technology Llp Rapidly disintegrating flavored film for precooked foods
US6656493B2 (en) * 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
RU2004107501A (en) * 2001-08-14 2005-02-20 Байотай Терапис Корпорейшн (Fi) METHOD FOR TREATMENT OF ALCOHOLISM OR ABUSE OF ALCOHOL
US6419903B1 (en) * 2001-08-20 2002-07-16 Colgate Palmolive Company Breath freshening film
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US7357891B2 (en) * 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070154527A1 (en) * 2001-10-12 2007-07-05 Monosoirx, Llc Topical film compositions for delivery of actives
US7910641B2 (en) * 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20100021526A1 (en) * 2001-10-12 2010-01-28 Monosol Rx, Llc Ph modulated films for delivery of actives
US7425292B2 (en) * 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
EP2351557B1 (en) 2001-10-12 2019-04-17 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity, process for ther production and drug delivery systems made therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7666337B2 (en) * 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20030099691A1 (en) * 2001-11-16 2003-05-29 Susan Lydzinski Films containing starch
JP2005522991A (en) * 2001-11-16 2005-08-04 ジボダン エス エー Edible film
KR100843001B1 (en) * 2002-01-16 2008-07-01 동화약품공업주식회사 Oral mucoadhesive film preparation
AU2003235716A1 (en) 2002-01-17 2003-07-30 Lts Lohmann Therapie-Systeme Ag Method for neutralizing or recycling carrier materials for film-like coatings
US20040247746A1 (en) * 2002-02-11 2004-12-09 Edizone, Lc Delivery units of thick orally soluble polymer
US20050100640A1 (en) * 2002-02-11 2005-05-12 Pearce Tony M. Microcapsule edibles
US20050003048A1 (en) * 2002-02-11 2005-01-06 Edizone, Lc Electrolyte-containing orally soluble films
US20040247744A1 (en) * 2002-02-11 2004-12-09 Edizone, Lc Vitamin-containing orally soluble films
US20040247649A1 (en) * 2002-02-11 2004-12-09 Edizone, Lc Medicine-containing orally soluble films
US20030224090A1 (en) * 2002-02-11 2003-12-04 Edizone, Lc Snacks of orally soluble edible films
CA2476250C (en) * 2002-02-13 2010-08-03 Michael K. Weibel Drug dose-form and method of manufacture
KR20030075213A (en) * 2002-03-16 2003-09-26 (주)케비젠 Watersoluble films comprising anti-cancer medicines and their preparation
US20030194420A1 (en) * 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
JP2005531569A (en) * 2002-05-24 2005-10-20 アグフア−ゲヴエルト At least partially degradable film containing active ingredient and process for its production
DE10224607B4 (en) * 2002-06-04 2008-03-13 Lts Lohmann Therapie-Systeme Ag Film-form, disintegratable preparations for drug release and process for their preparation
US6937455B2 (en) 2002-07-03 2005-08-30 Kronos Advanced Technologies, Inc. Spark management method and device
US7595065B2 (en) * 2002-06-25 2009-09-29 Wm. Wrigley Jr. Company Breath freshening and oral cleansing products with synergistic combinations of magnolia bark extract and essential oils
US7632525B2 (en) * 2002-06-25 2009-12-15 Wm. Wrigley Jr. Company Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents
US7347985B2 (en) * 2002-06-25 2008-03-25 Wm. Wrigley Jr. Company Breath freshening and oral cleansing product with magnolia bark extract
CN1662220A (en) * 2002-06-25 2005-08-31 Wm.雷格利Jr.公司 Breath freshening and oral cleansing product with cinnamaldehyde
US7150780B2 (en) * 2004-01-08 2006-12-19 Kronos Advanced Technology, Inc. Electrostatic air cleaning device
US7053565B2 (en) 2002-07-03 2006-05-30 Kronos Advanced Technologies, Inc. Electrostatic fluid accelerator for and a method of controlling fluid flow
US20030017208A1 (en) * 2002-07-19 2003-01-23 Francis Ignatious Electrospun pharmaceutical compositions
CN1747656B (en) * 2002-07-22 2011-05-04 莫诺索尔克斯有限公司 Packaging and dispensing of fast-dissolving forms
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7241411B2 (en) * 2002-08-23 2007-07-10 Acupac Packaging, Inc. Thin film strips
US6824829B2 (en) * 2002-08-23 2004-11-30 Acupac Packaging, Inc. Process for manufacturing thin film strips
US20040043134A1 (en) * 2002-08-27 2004-03-04 Corriveau Christine Leclair Rolled edible thin film products and methods of making same
DE60333196D1 (en) * 2002-08-27 2010-08-12 Wrigley W M Jun Co AIRBORNE AND MOUTHPROOF PRODUCT USING CARDAMOM L
WO2004019802A2 (en) * 2002-08-27 2004-03-11 Wm. Wrigley Jr. Company Breath freshening and oral cleansing product using carvacrol
US20040120991A1 (en) * 2002-09-07 2004-06-24 Mars Incorporated Edible films having distinct regions
US8524200B2 (en) 2002-09-11 2013-09-03 The Procter & Gamble Company Tooth whitening products
US20050019277A1 (en) * 2002-09-11 2005-01-27 The Procter & Gamble Company Tooth whitening products
US6916463B2 (en) * 2002-09-24 2005-07-12 The Procter & Gamble Company Oral products having an aesthetic layer
US6800295B2 (en) * 2002-10-09 2004-10-05 The Dial Corporation Water soluble sheet composition
GB0226076D0 (en) * 2002-11-08 2002-12-18 Rp Scherer Technologies Inc Improved formulations containing substituted imidazole derivatives
FI20022007A0 (en) * 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromucosal preparation and method of preparation thereof
DE10252726B4 (en) * 2002-11-13 2008-05-08 Lts Lohmann Therapie-Systeme Ag Multilayer transmucosal therapeutic system
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
CA2505833A1 (en) * 2002-11-14 2004-06-03 Innozen, Inc. Edible film for relief of cough or symptoms associated with pharyngitis
US20040191302A1 (en) 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
AU2003277788A1 (en) * 2002-11-14 2004-06-03 Givaudan Sa Edible film containing food acid
US20040131662A1 (en) * 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US20040111275A1 (en) * 2002-11-15 2004-06-10 Kroll David B. Methods for marketing and generating revenue from edible thin films
US20040096569A1 (en) * 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
AU2003302589A1 (en) 2002-12-02 2004-06-23 Kyukyu Pharmaceutical Co., Ltd. Method for producing orally administrable edible agent of laminate film form and pressure bonding apparatus of the agent.
WO2004049805A1 (en) * 2002-12-04 2004-06-17 Sankyo Agro Company, Limited Method of preventing wheat from mycotoxin contamination
DE10256775A1 (en) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Preparation of film forming composition for transmucosal delivery of nicotine used for treating tobacco addiction, includes converting nicotine free base to its salt with acid and/or incorporation of nicotine as salt
AU2003297752A1 (en) * 2002-12-06 2004-06-30 Monosolrx Llc Thin film delivery systems for volatile decongestants
US20040115137A1 (en) * 2002-12-17 2004-06-17 Verrall Andrew P. Water-soluble film for oral administration
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US6669929B1 (en) * 2002-12-30 2003-12-30 Colgate Palmolive Company Dentifrice containing functional film flakes
CA2514897C (en) * 2003-01-30 2012-08-28 Monosolrx Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20040156794A1 (en) * 2003-02-11 2004-08-12 Barkalow David G. Bioerodible and bioadhesive confectionery products and methods of making same
US7041311B2 (en) * 2003-02-28 2006-05-09 International Flavors & Fragrances Inc. Preparation for saliva flow
US20040228892A1 (en) * 2003-02-28 2004-11-18 Berry Craig J. Delivery system for cosmetic and skincare products
CA2520380A1 (en) * 2003-03-26 2004-10-14 The Procter & Gamble Company Rapidly dissolving edible film compositions with cellulose film forming polymers
CN1764436A (en) * 2003-03-26 2006-04-26 宝洁公司 Rapidly dissolving edible film compositions with improved film strength and stability
US20040202698A1 (en) * 2003-04-02 2004-10-14 The Procter & Gamble Company Drug delivery systems comprising an encapsulated active ingredient
US20050013847A1 (en) * 2003-04-14 2005-01-20 Fmc Corporation Delivery systems of homogeneous, thermoreversible alginate films
US20050019294A1 (en) * 2003-04-14 2005-01-27 Fmc Corporation Homogeneous, thermoreversible alginate films and soft capsules made therefrom
CA2522295C (en) * 2003-04-14 2012-02-07 Fmc Corporation Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
EP2716284A3 (en) 2003-05-28 2014-11-05 MonoSol RX LLC Polyethylene oxide-based films and drug delivery systems made herefrom
GB0312425D0 (en) * 2003-05-30 2003-07-09 Boots Co Plc Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith
US20040241294A1 (en) * 2003-05-31 2004-12-02 Barabolak Roman M. Edible films including aspartame and methods of making same
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
ATE369114T1 (en) * 2003-06-23 2007-08-15 Colgate Palmolive Co STABLE TOOTH CLEANING COMPOSITIONS
US20040258630A1 (en) 2003-06-23 2004-12-23 Boyd Thomas J. Antiplaque breath freshening consumable film
US8287843B2 (en) * 2003-06-23 2012-10-16 Colgate-Palmolive Company Antiplaque oral care compositions
DE10328942A1 (en) * 2003-06-27 2005-01-27 Lts Lohmann Therapie-Systeme Ag Transmucosal dosage forms with reduced mucous membrane irritation
UY28431A1 (en) 2003-07-24 2005-02-28 Smithkline Beecham Cororation MOVIES THAT DISSOLVE BY ORAL ROUTE
US7666396B2 (en) * 2003-09-11 2010-02-23 Kimberly-Clark Worldwide, Inc. Single-use moisturizing product
US20050080039A1 (en) * 2003-10-14 2005-04-14 Cp Kelco, U.S., Inc. Pectin films prepared from gamma irradiated pectin
ES2426990T3 (en) * 2003-10-24 2013-10-28 Adhesives Research, Inc. Disposable films for diagnostic devices
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
AU2004289248B2 (en) 2003-11-07 2012-05-03 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US7182964B2 (en) * 2003-11-13 2007-02-27 Dbc, Llc Dissolving thin film xanthone supplement
DE10354894A1 (en) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Oral formulations of deoxypeganine and their applications
DE10358747A1 (en) * 2003-12-12 2005-07-07 Lts Lohmann Therapie-Systeme Ag Dosage form based on crosslinked hydrophilic polymers
MXPA06006807A (en) * 2003-12-16 2006-08-23 Colgate Palmolive Co Oral and personal care compositions and methods.
DE102004002951A1 (en) * 2004-01-21 2005-08-11 Wella Ag Process for producing hair-setting products in film form
FR2865130B1 (en) * 2004-01-21 2007-10-05 Oreal ANHYDROUS FILM FOR MAKE-UP OR CARE OF LIPS.
KR20070007299A (en) 2004-01-30 2007-01-15 코리움 인터네셔널, 인크. Quick Melt Films for Delivery of Active Agents
US20050186256A1 (en) * 2004-02-20 2005-08-25 Dihel Deborah L. Dissolvable film comprising an active ingredient and method of manufacture
WO2005092271A1 (en) * 2004-03-03 2005-10-06 Warner-Lambert Company Llc Film compositions
US20050196355A1 (en) * 2004-03-03 2005-09-08 Constantine Georgiades Film products having controlled disintegration properties
US20050196348A1 (en) * 2004-03-03 2005-09-08 Constantine Georgiades Stabilized peroxide compositions
US20070269519A1 (en) * 2004-03-03 2007-11-22 Constantine Georgiades Whitening products
US20080003248A1 (en) * 2004-03-03 2008-01-03 Constantine Georgiades Whitening products
US20050196354A1 (en) * 2004-03-03 2005-09-08 Andre Soshinsky Film compositions
US20070190125A1 (en) * 2004-03-03 2007-08-16 Constantine Georgiades Positioning feature for aiding use of film or strip product
US20050208108A1 (en) * 2004-03-19 2005-09-22 Jannusch Leonard C Thermoplastic films and methods for making
US20050226906A1 (en) * 2004-04-08 2005-10-13 Micro Nutrient, Llc Nutrient system for individualized responsive dosing regimens
US7850987B2 (en) * 2004-04-08 2010-12-14 Micronutrient, Llc Nutrient composition(s) and system(s) for individualized, responsive dosing regimens
US7785619B2 (en) * 2004-04-08 2010-08-31 Micro Nutrient, Llc Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
WO2005102287A2 (en) * 2004-04-22 2005-11-03 Duocort Ab Pharmaceutical compositions for acute glucocorticoid therapy
US20050249782A1 (en) * 2004-05-04 2005-11-10 Victor Perry Drug delivery device
US7399482B1 (en) 2004-05-07 2008-07-15 Christine Horner Biernacki Thin film medication device and kit
US7972589B2 (en) * 2004-05-17 2011-07-05 Akzo Nobel N.V. Hair fixative film
EP1758554A1 (en) * 2004-06-12 2007-03-07 Passion For Life Healthcare Limited Soluble strip for oral or topical adminstration
EP1773366A4 (en) * 2004-06-22 2009-11-11 E L Management Corp Dissolvable film composition
US20060024425A1 (en) * 2004-07-30 2006-02-02 Wm. Wrigley Jr. Company Edible film compositions
KR20070048229A (en) 2004-08-05 2007-05-08 코리움 인터네셔널, 인크. Adhesive composition
DE102005003387A1 (en) * 2004-09-01 2006-03-02 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Plaster for administering active agents through body orifices, comprises adhesive and backing layers, both made of nonionic and anionic hydrocolloids in reverse ratios
SI1791791T1 (en) * 2004-09-27 2019-10-30 Special Water Patents B V Methods and compositions for treatment of water
NZ554525A (en) * 2004-09-30 2010-12-24 Hershey Co Sealed, edible film strip packets and methods of making and using them
JP4898113B2 (en) * 2004-12-02 2012-03-14 リンテック株式会社 Oral administration
EP1845979A4 (en) 2005-01-19 2009-11-11 Neurohealing Pharmaceuticals I Methods and compositions for decreasing saliva production
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DE102005007859A1 (en) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Procedures for a combination drug treatment, as well as suitable drug combinations
US7992575B2 (en) * 2005-02-28 2011-08-09 U.S. Smokeless Tobacco Company Use of chlorate, sulfur or ozone to reduce tobacco specific nitrosamines
BRPI0608289A2 (en) * 2005-03-10 2009-12-22 Mary Kay Inc compositions comprising incorporated water and agents incorporated in water sensitive matrices
DE102005015128B4 (en) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafers containing steroid hormones
WO2006107390A2 (en) 2005-04-04 2006-10-12 Kronos Advanced Technologies, Inc. An electrostatic fluid accelerator for and method of controlling a fluid flow
US20060228307A1 (en) * 2005-04-08 2006-10-12 Cao Group, Inc. Structures and methods for delivering topical compositions
JP2008539729A (en) * 2005-05-03 2008-11-20 イノゼン・インコーポレイテッド Edible film for transmucosal delivery of dietary supplements
US20060260366A1 (en) * 2005-05-18 2006-11-23 I+Dcreative, Llc Laundry appliance for washing small quantities of clothing
JP5215175B2 (en) * 2005-05-25 2013-06-19 ユーエス スモークレス タバコ カンパニー リミテッド ライアビリティ カンパニー Tobacco composition
US20060275364A1 (en) * 2005-05-26 2006-12-07 Ahmed Salah U Flexible Solid Dosage Forms and Methods of Making and Using the Same
WO2006135491A2 (en) * 2005-06-08 2006-12-21 Basf Aktiengesellschaft Medicament carrier composition and method of forming a film therefrom
DE102005033543A1 (en) * 2005-07-14 2007-01-18 Grünenthal GmbH A fragrance-containing transdermal therapeutic system
DE102005033943A1 (en) * 2005-07-20 2007-02-22 Hexal Ag Non-spitting, oral, fast-disintegrating film for a neuroleptic
US20090123545A1 (en) * 2005-07-21 2009-05-14 Ron Eyal S Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof
US20080213339A1 (en) * 2005-08-02 2008-09-04 Roger Imboden Pharmaceutical Composition Containing Indometacin and/or Acemetacin
EP3871693A1 (en) 2005-09-27 2021-09-01 Special Water Patents B.V. Compositions for oral care
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
US20070104769A1 (en) * 2005-11-04 2007-05-10 Lifescience Plus, Inc. Bioabsorbable hemostatic gauze
JP2009514597A (en) 2005-11-04 2009-04-09 ライフサイエンス・プラス・インコーポレイテッド Bioabsorbable hemostatic gauze
CN101321513A (en) * 2005-12-02 2008-12-10 Gic创新公司 Oral care medium with magnolia bark extract
CN101321537A (en) * 2005-12-02 2008-12-10 Gic创新公司 Confectionary compositions with magnolia bark extract
CA2631657C (en) * 2005-12-02 2013-10-01 Gic Innovations Company Chewable compositions with fast release magnolia bark extract
AU2006322050A1 (en) * 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
US20070148213A1 (en) * 2005-12-22 2007-06-28 Sayed Ibrahim Film containing compositions
SE530184C2 (en) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesive pharmaceutical film composition containing low viscous alginates
CN101346135A (en) * 2005-12-27 2009-01-14 莫诺索尔克斯有限公司 pH adjusted membranes for active agent delivery
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
CA2636026A1 (en) * 2006-01-20 2007-07-26 Monosol Rx, Llc Film lined pouch and method of manufacturing this pouch
JP4668798B2 (en) * 2006-01-25 2011-04-13 株式会社ツキオカ Water-soluble cleaning film
BRPI0708068A2 (en) 2006-02-17 2011-05-17 Novartis Ag collapsible buccal films
MX2008011823A (en) * 2006-03-16 2008-10-31 Novartis Ag SOLID DOSAGE FORM CONTAINING AN ACTIVE AGENT OF COVERED FLAVOR.
US20070231387A1 (en) * 2006-04-04 2007-10-04 Luigi Levi Film-coated solid dosage forms
JP5844028B2 (en) 2006-04-04 2016-01-13 ケージー アクキュイシチオン エルエルシー Oral dosage forms containing antiplatelet agents and acid inhibitors
WO2007127810A2 (en) * 2006-04-25 2007-11-08 Kronos Advanced Technologies, Inc. Electrostatic loudspeaker and method of acoustic waves generation
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
DE602007009377D1 (en) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM
US20080152761A1 (en) * 2006-12-20 2008-06-26 Shiji Shen Packaging of Food Products with Pullulan Films
EP3067044B1 (en) 2006-07-21 2019-03-27 BioDelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US8642016B2 (en) * 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US7884135B2 (en) * 2006-08-14 2011-02-08 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US8334327B2 (en) * 2006-08-31 2012-12-18 Kimberly-Clark Worldwide, Inc. Highly breathable biodegradable films
AU2007297697A1 (en) * 2006-09-20 2008-03-27 Monosol Rx Llc Edible water-soluble film containing a foam reducing flavoring agent
EP2077824A4 (en) * 2006-09-29 2012-07-18 Monosol Rx Llc Film embedded packaging and method of making same
US20080131467A1 (en) * 2006-11-30 2008-06-05 Dennis Nelson Film-coated solid dosage form
CN101616660A (en) * 2007-01-12 2009-12-30 莫诺索尔克斯有限公司 High dose film compositions and methods of making the same
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
CN101754755A (en) * 2007-02-15 2010-06-23 德尔玛-杨有限公司 Compositions and methods for enhancing transmucosal delivery
US20080220029A1 (en) * 2007-03-05 2008-09-11 Charlene Ng Fast-dissolving/disintegrating film preparation having high proportion of active
WO2008112124A2 (en) * 2007-03-07 2008-09-18 Novartis Ag Orally administrable films
US20090011115A1 (en) * 2007-03-13 2009-01-08 Foss Carter D Edible Pullulan Films Containing Flavoring
US20090087468A1 (en) * 2007-03-28 2009-04-02 Serena Stephenson Semi-Rigid Gel Article For Disinfecting A Surface
WO2008127902A2 (en) * 2007-04-12 2008-10-23 Tate & Lyle Ingredients Americas, Inc. Pullulan film containing sweetener
HRP20130259T1 (en) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. SUSPENSION FORMULATIONS OF INSULINOTROPIC PEPTIDES AND THEIR USE
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
US8765155B2 (en) * 2007-08-30 2014-07-01 Colgate-Palmolive Company Oral care strip or tape and methods of use and manufacture thereof
US9271524B1 (en) 2007-09-07 2016-03-01 U.S. Smokeless Tobacco Company Tobacco having reduced tobacco specific nitrosamine content
US20090098192A1 (en) * 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
EP2217102B1 (en) 2007-10-11 2023-04-05 Philip Morris Products S.A. Smokeless tobacco product
US9125434B2 (en) * 2007-10-11 2015-09-08 Philip Morris Products S.A. Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet
EP2200446A4 (en) 2007-10-12 2011-11-30 Euthanex Corp Method and apparatus for euthanizing animals
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
US20090142452A1 (en) * 2007-11-19 2009-06-04 Michael David Campbell Dissolvable Orally Consumable Flavored Sensual Enhancement Films
US20090253754A1 (en) * 2007-12-04 2009-10-08 Francesca Selmin Fast dissolving films and coatings for controlled release of flavors, active pharmaceutical ingredients, food substances, and nicotine
US8227658B2 (en) 2007-12-14 2012-07-24 Kimberly-Clark Worldwide, Inc Film formed from a blend of biodegradable aliphatic-aromatic copolyesters
AU2009214193A1 (en) * 2008-02-13 2009-08-20 Bayer Intellectual Property Gmbh Estradiol-containing drug delivery system
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
AU2009214307A1 (en) * 2008-02-13 2009-08-20 Bayer Intellectual Property Gmbh Drug delivery system with stabilising effect
US7998888B2 (en) * 2008-03-28 2011-08-16 Kimberly-Clark Worldwide, Inc. Thermoplastic starch for use in melt-extruded substrates
DE102008023345B4 (en) 2008-05-13 2014-12-04 Lts Lohmann Therapie-Systeme Ag Film-like preparation with oily substances for oral administration
US9265779B2 (en) 2008-05-13 2016-02-23 Lts Lohmann Therapie-Systeme Ag Method of using a film-shaped preparation comprising oily substances for oral administration
US8147965B2 (en) 2008-05-14 2012-04-03 Kimberly-Clark Worldwide, Inc. Water-sensitive film containing thermoplastic polyurethane
US8338508B2 (en) * 2008-05-14 2012-12-25 Kimberly-Clark Worldwide, Inc. Water-sensitive film containing an olefinic elastomer
ES2525123T3 (en) 2008-06-04 2014-12-17 Colgate-Palmolive Company Implementation for oral care with cavitation system
ES2663777T3 (en) * 2008-06-23 2018-04-17 Biodelivery Sciences International, Inc. Multidirectional mucosal administration devices and methods of use
US8927617B2 (en) * 2008-06-30 2015-01-06 Kimberly-Clark Worldwide, Inc. Fragranced water-sensitive film
US8759279B2 (en) * 2008-06-30 2014-06-24 Kimberly-Clark Worldwide, Inc. Fragranced biodegradable film
US8188185B2 (en) * 2008-06-30 2012-05-29 Kimberly-Clark Worldwide, Inc. Biodegradable packaging film
US20110305768A1 (en) * 2008-07-01 2011-12-15 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
FR2933959B1 (en) * 2008-07-16 2010-09-10 Roquette Freres PROCESS FOR PRODUCING FILMS DIRECTLY IN ALVEOL
US20100040727A1 (en) * 2008-08-18 2010-02-18 Monosol Rx, Llc Method for Improving Uniformity of Content in Edible Film Manufacturing
US8282954B2 (en) * 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
US8329601B2 (en) 2008-12-18 2012-12-11 Kimberly-Clark Worldwide, Inc. Biodegradable and renewable film
US8283006B2 (en) * 2008-12-18 2012-10-09 Kimberly-Clark Worldwide, Inc. Injection molding material containing starch and plant protein
WO2010083035A2 (en) 2009-01-14 2010-07-22 Corium International, Inc. Transdermal administration of tamsulosin
US20100183717A1 (en) 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
US9492505B2 (en) * 2009-01-21 2016-11-15 University Of Florida Research Foundation, Inc. Satiation peptide administration
JP5674480B2 (en) * 2009-01-29 2015-02-25 日東電工株式会社 Intraoral film-form base and preparation
WO2010086989A1 (en) * 2009-01-29 2010-08-05 日東電工株式会社 Intraoral film-shaped base and preparation
AU2010220056B2 (en) 2009-03-04 2015-04-02 Regenera Pharma Ltd. Therapeutic uses of mastic gum fractions
EP3578191A1 (en) 2009-03-04 2019-12-11 Regenera Pharma Ltd. Compositions of polymeric myrcene
US20100256215A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Menthol-Melatonin Dissolving Film
US20100256197A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Nicotine Dissolving Film With Or Without Menthol
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
TWI396554B (en) * 2009-05-26 2013-05-21 Colgate Palmolive Co Oral care formulations that enhance amount of soluble zinc
CN105411869A (en) 2009-05-26 2016-03-23 高露洁-棕榄公司 Dentifrice Composition
CA2760227C (en) 2009-05-26 2015-05-05 Colgate-Palmolive Company Dentifrice composition
EP2442650B2 (en) 2009-06-12 2025-05-14 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
CA2767950C (en) 2009-07-27 2019-11-12 Suresensors Ltd Improvements relating to sensor devices
CN102470078A (en) * 2009-07-30 2012-05-23 宝洁公司 Oral Care Products
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
SMT201700583T1 (en) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CA2779025A1 (en) 2009-10-28 2011-05-05 Regenera Pharma Ltd. Therapeutic uses of oligomeric and polymeric monoterpenes
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
BR112012013331A2 (en) 2009-12-04 2016-03-01 Colgate Palmolive Co soluble films containing high concentrations of nonionic surfactants such as polysorbates to improve high solid loads
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
CN102753196A (en) * 2009-12-10 2012-10-24 莫诺索尔克斯有限公司 Ph sensitive compounds in taste masking within oral thin film strips
EP2519225B1 (en) 2009-12-30 2015-03-25 Novartis AG Melt extruded nicotine thin strips
EP2519224A1 (en) 2009-12-30 2012-11-07 Novartis AG Melt extruded thin strips containing coated pharmaceutical actives
AR079890A1 (en) * 2010-01-13 2012-02-29 Colgate Palmolive Co STABILIZATION OF ZINC OXIDE FILMS IN ORAL COMPOSITIONS
TWI435733B (en) 2010-01-29 2014-05-01 美國棕欖公司 Oral care formulation for bad breath control
JP5751868B2 (en) 2010-03-30 2015-07-22 日東電工株式会社 Film-form preparation and method for producing the same
US20110276522A1 (en) * 2010-03-31 2011-11-10 Kehoe Gary S Standardization and reconstitution of phytochemicals for medical dispensation
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20110269844A1 (en) * 2010-05-03 2011-11-03 Innoteq, Inc. Thin film with propofol active ingredient
US20110269841A1 (en) * 2010-05-03 2011-11-03 Innoteq, Inc. Thin film with methadone active ingredient
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
AU2011265294B2 (en) 2010-06-10 2015-01-22 Aquestive Therapeutics, Inc. Nanoparticle film delivery systems
US9161890B2 (en) 2010-06-30 2015-10-20 Colgate-Palmolive Company Multilayer films for delivery of flavor
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
EP3581177A3 (en) 2010-09-07 2020-02-26 Regenera Pharma Ltd. Compositions comprising acidic extracts of mastic gum
DE102010048408A1 (en) 2010-10-15 2012-04-19 Lts Lohmann Therapie-Systeme Ag Laminate with improved water retention behavior
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US10238684B2 (en) 2010-11-18 2019-03-26 Foundational Biosystems, Llc Micro- and nano-quantity sleep enhancing nutrient composition and method of enhancing central nervous system protein clearance using same
US9095530B2 (en) * 2010-12-07 2015-08-04 Colgate-Palmolive Company Oral and personal care compositions
CA3115378A1 (en) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Sublingual films comprising apomorphine and an organic base
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012149326A1 (en) 2011-04-29 2012-11-01 Massachusetts Institute Of Technology Layer processing for pharmaceuticals
US8241661B1 (en) * 2011-06-24 2012-08-14 Fuisz Richard C Biocompatible film with variable cross-sectional properties
KR101303479B1 (en) * 2011-07-28 2013-09-06 (주)씨엘팜 Composition for edible film and pharmaceutical preparation for edible film containing drugs
AU2012296346A1 (en) 2011-08-18 2014-04-03 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
CN110496108A (en) 2011-12-14 2019-11-26 Lts勒曼治疗系统股份公司 The wafer capsule preparation and capsule preparations with the dissolution rate improved for fenofibrate
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
JP5841433B2 (en) 2012-01-11 2016-01-13 日東電工株式会社 Intraoral film-form base and preparation
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
FR2990349B1 (en) 2012-05-11 2014-08-08 Pf Medicament FAST DISINTEGRATING MONOLAYER FILM AND ITS USE IN ORAL HYGIENE
JP6050031B2 (en) * 2012-06-01 2016-12-21 森下仁丹株式会社 Film formulation
RU2510558C1 (en) * 2012-07-19 2014-03-27 Александр Викторович Атаманов Wireless charging system for low-power consumers of electrical energy
EP2874824B1 (en) 2012-07-23 2025-04-30 Crayola, LLC Dissolvable films and methods of using the same
CN104884079B (en) 2012-11-14 2021-02-12 史密夫和内修公司 Stable thermolysin hydrogel
US10829621B2 (en) 2013-01-11 2020-11-10 Monosol, Llc Edible water-soluble film
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
US11452698B2 (en) 2013-03-15 2022-09-27 Smith & Nephew, Inc. Dissolvable gel-forming film for delivery of active agents
US9303918B2 (en) 2013-03-15 2016-04-05 Monosol Rx, Llc Process for drying a wet film with control of loss on drying
US20140275194A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Films and drug delivery systems for rizatriptan
WO2014145699A1 (en) 2013-03-15 2014-09-18 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
US9278050B2 (en) 2013-04-01 2016-03-08 Trevor Anderson Dissolvable medication administration bag and method of using the same
AU2014298130A1 (en) 2013-07-31 2016-02-11 Intelgenx Corp. Instantly wettable oral film dosage form without surfactant or polyalcohol
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
EP3089854B1 (en) 2013-12-31 2018-11-21 Johnson & Johnson Consumer Inc. Single-pass process for forming a multilayered shaped film product, product and apparatus
KR102226590B1 (en) 2013-12-31 2021-03-12 존슨 앤드 존슨 컨수머 인코포레이티드 Process for forming a shaped film product
EP3091968B1 (en) 2013-12-31 2025-10-29 Kenvue Brands LLC Process for forming a multilayered shaped film
MX2021014508A (en) 2014-04-04 2023-05-18 Intra Cellular Therapies Inc Organic compounds.
WO2015179461A1 (en) 2014-05-20 2015-11-26 Massachusetts Institute Of Technology Plasticity induced bonding
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP2017537127A (en) * 2014-12-09 2017-12-14 モノソル アールエックス リミテッド ライアビリティ カンパニー Film products based on linear polysaccharides
KR101695071B1 (en) 2014-12-26 2017-01-11 연세대학교 산학협력단 Pharmaceutical composition of liquid state drug dispersed film form
JP7211706B2 (en) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド Method for treating Parkinson's disease by administering apomorphine to oral mucosa
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
US10532046B2 (en) 2015-12-03 2020-01-14 Niconovum Usa, Inc. Multi-phase delivery compositions and products incorporating such compositions
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
CA3048820A1 (en) * 2015-12-30 2017-07-06 Next Generation Labs, LLC Nicotine replacement therapy products comprising synthetic nicotine
BR112018015283B1 (en) 2016-01-26 2023-09-26 Intra-Cellular Therapies, Inc ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS AND USE THEREOF FOR THE TREATMENT OR PROPHYLAXIS OF A DISORDER OF THE CENTRAL NERVOUS SYSTEM
AU2017238842B2 (en) 2016-03-25 2019-06-20 Intra-Cellular Therapies, Inc. Organic compounds
US11311633B2 (en) 2016-04-16 2022-04-26 University Of Florida Research Foundation, Incorporated Satiation peptides for weight loss and altered taste sensitivity
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
EP3452023A1 (en) 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
BR112018073511A2 (en) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. glucagon receptor selective polypeptides and methods of use
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018085495A2 (en) * 2016-11-02 2018-05-11 Board Of Regents, The University Of Texas System Dissolvable films and methods of their use
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
MX2019008006A (en) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc METHODS INCLUDING THE CONTINUOUS ADMINISTRATION OF A GLP-1 RECEPTOR AGONIST AND THE CO-ADMINISTRATION OF A DRUG.
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A PHARMACEUTICAL FORMULATION COMPRISING 1-(4-FLUORO-PHENYL)-4-((6bR,10aS)-2,2-D2-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H,7H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8-YL)-BUTAN-1-ONE AND USES THEREOF
US9901545B1 (en) 2017-04-13 2018-02-27 Richard C. Fuisz Method and composition for making an oral soluble film, containing at least one active agent
US10238600B2 (en) 2017-04-13 2019-03-26 Richard C. Fuisz Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent
WO2019006010A1 (en) * 2017-06-27 2019-01-03 The Coca-Cola Company Oral sweetener compositions and methods
CA3094204A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
CA3094949A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Deuterated heterocycle fused gamma-carbolines
US11911492B2 (en) 2018-05-14 2024-02-27 The Procter & Gamble Company Oral care compositions comprising metal ions
US10835455B2 (en) 2018-05-14 2020-11-17 The Procter & Gamble Company Oral care compositions comprising metal ions
CN112384504A (en) 2018-06-15 2021-02-19 R.J.雷诺兹烟草公司 Purification of nicotine
GB2574878A (en) * 2018-06-22 2019-12-25 Biofilm Ltd Oral compositions and mucoadhesive thin films formed therefrom
EP3843729A4 (en) 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. Novel compositions and methods
US10695345B2 (en) 2018-08-31 2020-06-30 Intra-Cellular Therapies, Inc. Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
JP7546546B2 (en) 2018-08-31 2024-09-06 イントラ－セルラー・セラピーズ・インコーポレイテッド New Method
US11235013B2 (en) 2018-09-04 2022-02-01 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US10813889B2 (en) 2018-09-04 2020-10-27 Babak Ghalili Cannabinoid and menthol compositions and methods
US20210369703A1 (en) * 2018-10-18 2021-12-02 Avior, Inc. Method and device of treating chronic kidney disease-associated pruritus
JP7388075B2 (en) * 2019-02-18 2023-11-29 富士フイルムビジネスイノベーション株式会社 modeling equipment
CN113905711B (en) 2019-04-25 2024-04-16 宝洁公司 Washable multi-phase composition
JP2022529192A (en) 2019-04-25 2022-06-17 ザ プロクター アンド ギャンブル カンパニー Systems and methods for delivering activators
CN113747872A (en) 2019-04-25 2021-12-03 宝洁公司 Oral care compositions for active agent delivery
US10780032B1 (en) 2019-04-25 2020-09-22 The Procter & Gamble Company Oral care compositions for active agent delivery
BR112022000231A2 (en) 2019-07-07 2022-02-22 Intra Cellular Therapies Inc new methods
WO2021168696A1 (en) 2020-02-26 2021-09-02 The Procter & Gamble Company Oral care compositions for gum health
WO2021168684A1 (en) 2020-02-26 2021-09-02 The Procter & Gamble Company Oral care compositions for gum health
WO2021177937A1 (en) * 2020-03-02 2021-09-10 Babak Ghalili Cannabinoid and menthol compositions and methods
WO2021177941A1 (en) * 2020-03-03 2021-09-10 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
DE102020112143B4 (en) 2020-05-05 2022-03-17 Lts Lohmann Therapie-Systeme Ag Nicotine - Corona
US11173114B1 (en) 2020-07-10 2021-11-16 Nova Thin Film Pharmaceuticals Llc Method and system for manufacturing and oral soluble films and oral soluble films made by thereby
EP4294368A4 (en) 2021-02-19 2024-11-06 Nova Thin Film Pharmaceuticals LLC Method and system for manufacturing oral soluble films, compositions of oral soluble films, oral soluble films made by thereby, and methods of use thereof
EP4392010A1 (en) 2021-08-23 2024-07-03 The Procter & Gamble Company Oral care compositions for gum health
WO2023023884A1 (en) 2021-08-23 2023-03-02 The Procter & Gamble Company Oral care compositions for gum health
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
KR20250033561A (en) * 2023-08-31 2025-03-10 주식회사 케이티앤지 Nicotine pouch and manufacturing method for the same
KR20250032618A (en) * 2023-08-31 2025-03-07 주식회사 케이티앤지 Packaging material for nicotine pouch, nicotine pouch including the same, and manufacturing method thereof
KR20250051993A (en) * 2023-10-11 2025-04-18 서울과학기술대학교 산학협력단 Buccal adhesive patch and manufacturing method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332789A (en) * 1975-12-15 1982-06-01 Hoffmann-La Roche Inc. Pharmaceutical unit dosage forms
US4486436A (en) * 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4517173A (en) * 1980-09-26 1985-05-14 Nippon Soda Co. Ltd. Mucous membrane-adhering film preparation and process for its preparation
US5032387A (en) * 1986-11-06 1991-07-16 Princeton Pharmaceutical Inc. Dental and oral hygiene preparations
US5780045A (en) * 1992-05-18 1998-07-14 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931824A (en) * 1973-09-10 1976-01-13 Celanese Corporation Smoking materials
US4007290A (en) * 1974-01-09 1977-02-08 General Foods Corporation Caffeine antagonim
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
DE2432925C3 (en) * 1974-07-05 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen Film-shaped medicinal products
US4136145A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
DE2449865B2 (en) * 1974-10-17 1981-06-19 Schering Ag Berlin Und Bergkamen, 1000 Berlin Film-shaped medicinal product
IN142428B (en) * 1974-07-05 1977-07-09 Schering Ag
US4082841A (en) * 1975-10-10 1978-04-04 Lever Brothers Company Dentifrice
US4031200A (en) * 1975-12-15 1977-06-21 Hoffmann-La Roche Inc. Manufacture of pharmaceutical unit dosage forms
US4029757A (en) * 1975-12-15 1977-06-14 Hoffmann-La Roche Inc. Manufacture of pharmaceutical unit dosage forms
US4029758A (en) * 1975-12-15 1977-06-14 Hoffmann-La Roche Inc. Preparation of pharmaceutical unit dosage forms
ZA767136B (en) * 1975-12-15 1977-10-26 Hoffmann La Roche Novel dosage form
US4713239A (en) * 1979-05-29 1987-12-15 Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk Sssr Antianginal film and method of treating ischemic heart disease
GB8301659D0 (en) 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
JPS6130516A (en) * 1984-07-20 1986-02-12 Nichiban Co Ltd Mucosa adhesive pharmaceutical
JPS6185315A (en) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk Sheet-form preparation
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
EP0200508B1 (en) * 1985-04-27 1991-10-02 Nitto Denko Corporation Adhesive oral bandages and oral pharmaceutical preparations
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5783207A (en) 1985-05-01 1998-07-21 University Of Utah Research Foundation Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
JPS61280423A (en) * 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk Mucosal application agent in oral cavity
JPS63501794A (en) * 1985-10-09 1988-07-21 デジテイン　アルツナイミツテル　ゲ−エムベ−ハ− Methods for providing pharmaceutically active substances, reagents, and other active substances or for producing dosage forms
US5229164A (en) * 1985-12-19 1993-07-20 Capsoid Pharma Gmbh Process for producing individually dosed administration forms
JPH0729915B2 (en) * 1986-02-01 1995-04-05 帝國製薬株式会社 Sheet-shaped oral patch
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4713243A (en) * 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
DE3630603A1 (en) * 1986-09-09 1988-03-10 Desitin Arzneimittel Gmbh PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL ACTIVE SUBSTANCES, REAGENTS OR THE LIKE, AND METHOD FOR THE PRODUCTION THEREOF
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US4855142A (en) * 1987-02-27 1989-08-08 Ciba-Geigy Corporation Pharmaceutical plaster
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5234957A (en) * 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4900552A (en) * 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
DE3827561C1 (en) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
JP2656338B2 (en) * 1989-01-31 1997-09-24 日東電工株式会社 Oral mucosa patch preparation
JPH02258718A (en) * 1989-03-31 1990-10-19 Nippon Kayaku Co Ltd Pasty base and pharmaceutical
US5824334A (en) * 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
CA2044172A1 (en) * 1989-10-14 1991-04-15 Wolfgang Schmidt Oral and dental hygiene preparation
US5354551A (en) * 1989-10-14 1994-10-11 Desitin Arzneimittel Gmbh Oral and dental hygiene preparation
US5525351A (en) * 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
JPH03209327A (en) * 1990-01-11 1991-09-12 Teikoku Seiyaku Kk Nicotine-containing cataplasm for oral cavity membrane
GB9009390D0 (en) 1990-04-26 1990-06-20 Smith Kline French Lab Pharmaceutical compositions
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
DE4018247A1 (en) * 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts MANUFACTURING METHOD FOR QUICK-DISINFITTING FILM-SHAPED PHARMACEUTICAL FORMS
JPH06502622A (en) * 1990-07-23 1994-03-24 アルザ・コーポレーション Oral penetration device for administering nicotine
US5147654A (en) 1990-07-23 1992-09-15 Alza Corporation Oral osmotic device for delivering nicotine
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
ES2071336T3 (en) * 1990-10-25 1995-06-16 Boots Co Plc Mouthwash
SE466134B (en) * 1990-11-22 1992-01-07 Kabi Pharmacia Ab GEL-PHARMACEUTICAL LIQUID COMPOSITION AND APPLICATION THEREOF IN PHARMACEUTICAL COMPOSITIONS
IT1250421B (en) * 1991-05-30 1995-04-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH BIO-ADHESIVE PROPERTIES.
JPH05236885A (en) 1991-07-17 1993-09-17 Tazawa Toshihiko Flavoring and refreshing food formed into film
JPH0541602A (en) 1991-08-06 1993-02-19 Fujitsu General Ltd Primary radiator for both circular and linear polarization
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
AU658681B2 (en) * 1991-10-23 1995-04-27 Block Drug Company Inc., The Penetration enhancement of topically applied formulations
US5414005A (en) * 1993-10-28 1995-05-09 Dynagen, Inc. Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
WO1995005416A2 (en) * 1993-08-19 1995-02-23 Cygnus Therapeutic Systems Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
AU1554595A (en) 1993-12-28 1995-07-17 Richard D. Frank Pakaging and dispensing device for sterile articles
EP0743842B1 (en) 1994-03-07 2003-08-13 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
JPH09503023A (en) 1994-06-16 1997-03-25 フアルマシア・エツセ・ピー・アー Bioadhesive starch and method for producing the starch
WO1996000072A1 (en) 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
US6436407B1 (en) * 1994-08-26 2002-08-20 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic adjuvant
AU5299996A (en) * 1995-02-23 1996-09-11 Cygnus, Inc. Water-soluble pressure-sensitive mucoadhesive
FR2733684B1 (en) * 1995-05-03 1997-05-30 Cird Galderma USE OF RETINOIDS IN A COSMETIC COMPOSITION OR FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION
JP2791317B2 (en) 1995-12-26 1998-08-27 株式会社三和化学研究所 Multilayer film preparation
FR2742989B1 (en) * 1995-12-29 1998-01-23 Adir BIOADHESIVE PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS
DE19615820A1 (en) * 1996-04-06 1997-10-09 Holger Specht Dental care products containing orally absorbable components
US5955098A (en) 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US5853740A (en) * 1996-08-07 1998-12-29 Abbott Laboratories Delivery system for pharmaceutical agents encapsulated with oils
US5871905A (en) * 1996-09-04 1999-02-16 Epitope, Inc. Reduction of false positives in oral-fluid based immunoassays
DE19646392A1 (en) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery
JP3460538B2 (en) 1997-10-08 2003-10-27 救急薬品工業株式会社 Fast dissolving film preparation
DE19837073A1 (en) 1998-08-17 2000-03-23 Lohmann Therapie Syst Lts Foil-shaped drug carriers
US6165512A (en) * 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6335023B1 (en) * 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
DE19932603A1 (en) 1999-07-13 2001-01-25 Gruenenthal Gmbh Multi-layer film containing active substance made of in-situ cross-linked hydrophilic polymers
CN1252154C (en) 1999-07-22 2006-04-19 沃纳-兰伯特公司 Pullulan film compositions
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
JP4044709B2 (en) 1999-11-19 2008-02-06 信越化学工業株式会社 Water-based film coating agent and oral solid preparation
DE10032456A1 (en) 2000-07-04 2002-01-31 Lohmann Therapie Syst Lts Rapidly disintegrating dosage form for the release of active substances in the mouth or in the body cavities
DE10107659B4 (en) 2001-02-19 2008-03-13 Lts Lohmann Therapie-Systeme Ag Mucoadhesive disintegratable drug preparation for drug administration in veterinary and human medicine
US20030068376A1 (en) 2001-04-20 2003-04-10 Lavipharm Laboratories Inc. Intraoral delivery of nicotine for smoking cessation
KR100890180B1 (en) 2001-04-24 2009-03-25 린텍 가부시키가이샤 Oral and Oral Dosing Agents
WO2003003957A1 (en) * 2001-07-06 2003-01-16 Lavipharm Laboratories Inc. Quick dissolving oral mucosal drug delivery device with moisture barrier coating
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
JP5089840B2 (en) 2001-09-25 2012-12-05 救急薬品工業株式会社 Nicotine-containing film preparation
ES2444951T5 (en) 2001-10-12 2022-06-28 Aquestive Therapeutics Inc Uniform films for a fast-dissolving dosage form incorporating taste-masking compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332789A (en) * 1975-12-15 1982-06-01 Hoffmann-La Roche Inc. Pharmaceutical unit dosage forms
US4517173A (en) * 1980-09-26 1985-05-14 Nippon Soda Co. Ltd. Mucous membrane-adhering film preparation and process for its preparation
US4486436A (en) * 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US5032387A (en) * 1986-11-06 1991-07-16 Princeton Pharmaceutical Inc. Dental and oral hygiene preparations
US5780045A (en) * 1992-05-18 1998-07-14 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129799B2 (en) 2011-04-12 2021-09-28 Aquestive Therapeutics, Inc. Dual lane coating
WO2019121660A1 (en) * 2017-12-20 2019-06-27 Firmenich Sa Oral care compositions
US11389383B2 (en) 2017-12-20 2022-07-19 Firmenich Sa Oral care compositions
US11938209B2 (en) 2017-12-20 2024-03-26 Firmenich Sa Oral care compositions
US11723863B2 (en) 2018-06-22 2023-08-15 Church & Dwight Co., Inc. Oral care compositions comprising benzocaine and mucoadhesive thin films formed therefrom

Also Published As

Publication number Publication date
DK0936905T3 (en) 2003-11-24
HU228464B1 (en) 2013-03-28
JP4063331B2 (en) 2008-03-19
EP0936905A1 (en) 1999-08-25
US6284264B1 (en) 2001-09-04
PT936905E (en) 2004-01-30
PT1362584E (en) 2009-05-07
SK285100B6 (en) 2006-06-01
NZ335063A (en) 2000-12-22
JP2005247876A (en) 2005-09-15
HU230022B1 (en) 2015-05-28
SK62299A3 (en) 2000-03-13
HUP9904207A2 (en) 2000-04-28
WO1998020862A1 (en) 1998-05-22
JP4817721B2 (en) 2011-11-16
HK1035316A1 (en) 2002-02-01
NO991921D0 (en) 1999-04-22
ID22526A (en) 1999-10-28
TW200305444A (en) 2003-11-01
CZ164799A3 (en) 1999-08-11
CA2265651C (en) 2004-03-16
HU0500666D0 (en) 2005-09-28
DE19646392A1 (en) 1998-05-14
CZ297354B6 (en) 2006-11-15
JP2010006832A (en) 2010-01-14
NO20053307D0 (en) 2005-07-06
KR100569847B1 (en) 2006-04-12
NO20053307L (en) 1999-04-02
US6709671B2 (en) 2004-03-23
ATE422157T1 (en) 2009-02-15
US20020127190A1 (en) 2002-09-12
JP2001504106A (en) 2001-03-27
IL169984A0 (en) 2009-02-11
AU4868297A (en) 1998-06-03
EP0936905B1 (en) 2003-08-27
US6592887B2 (en) 2003-07-15
KR20050088161A (en) 2005-09-01
ATE247954T1 (en) 2003-09-15
DE59710670D1 (en) 2003-10-02
ES2322699T3 (en) 2009-06-25
MY125548A (en) 2006-08-30
CA2265651A1 (en) 1998-05-22
US8865202B2 (en) 2014-10-21
AU739698B2 (en) 2001-10-18
SK285999B6 (en) 2008-01-07
US20040156885A1 (en) 2004-08-12
EP1362584A1 (en) 2003-11-19
IL169984A (en) 2012-06-28
TR199901633T2 (en) 1999-09-21
ZA9710093B (en) 1998-05-25
KR100604995B1 (en) 2006-07-26
US20010046511A1 (en) 2001-11-29
US5948430A (en) 1999-09-07
TW533083B (en) 2003-05-21
DK1362584T3 (en) 2009-06-02
IL129819A0 (en) 2000-02-29
ES2206692T3 (en) 2004-05-16
HUP9904207A3 (en) 2001-04-28
NO991921L (en) 1999-04-22
US20020150544A1 (en) 2002-10-17
DE29724755U1 (en) 2003-10-02
EP1362584B1 (en) 2009-02-04
NO325073B1 (en) 2008-01-28
DE59712993D1 (en) 2009-03-19
US6177096B1 (en) 2001-01-23
TWI250029B (en) 2006-03-01
KR20000053184A (en) 2000-08-25
PL190376B1 (en) 2005-12-30
SI0936905T1 (en) 2004-02-29

Similar Documents

Publication Publication Date Title
US6177096B1 (en) Water soluble film for oral administration with instant wettability
JP2007509172A (en) Rapidly degradable film for delivering pharmaceutical or cosmetic agents
CA3104416A1 (en) Oral compositions and mucoadhesive thin films formed therefrom
HK1035316B (en) Immediate wettability water soluble film or water soluble layer for oral application

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION